t-MN are characterized by poor prognosis and a specific karyotype/genetic signature, enriched in complex cytogenetic abnormalities and high-risk mutations, especially TP53, detected in approximately 20–40% of cases [4]. This evidence concerns the gene TP53 and therapy-related myeloid neoplasm.